AIMS: The pharmacokinetics of intramuscular artemether and its major plasma metabolite-dihydroartemisinin, were investigated in patients with severe manifestations of falciparum malaria. METHODS: Six severe falciparum malaria patients with acute renal failure (ARF) and 11 without ARF were recruited into the study. They were treated with intramuscular artemether at a loading dose of 160 mg, followed by daily doses of 80 mg for another 6 days (total dose 640 mg). RESULTS: Patients with and without ARF showed a good initial response to treatment; the parasite and fever clearance times were 66(30-164) and 76(36-140) h [median(range)], respectively. None had reappearance of parasitaemia in their peripheral blood smear within 7 days of initiation of treatment. In comatose patients, the time to recovery of consciousness was 51.6(22-144) h. Artemether was detected in plasma as early as 1 h after a 160 mg dose, and declined to undetectable levels within 24 h in most cases. Patients with ARF had significantly higher Cmax [2.38(1.89-3.95) vs 1.56(1.05-3.38) ng ml(-1) mg(-1) dose], AUC [35.4(22-52.9) vs 25.2(13.4-52.9) ng ml(-1) h mg(-1) dose], and lower Vz/F [5.45(3.2-6.9) vs 8.6(4.2-12.3) l kg(-1)] and CL/F [7.4(5.4-13.8) vs 19.1(8.5-25.1) ml min(-1) kg(-1)] when compared with those without ARF. In addition, t1/2,z was significantly longer in ARF patients [7.0(5.5-10.0) vs 5.7(4.2-6.6) h]. The pharmacokinetics of dihydroartemisinin in the two groups of patients were comparable. CONCLUSIONS: ARF significantly modified the pharmacokinetics of intramuscular artemether. The changes could be attributed to either improved absorption/bioavailability, a reduction of systemic clearance, or a change in plasma protein binding of the drug.
AIMS: The pharmacokinetics of intramuscular artemether and its major plasma metabolite-dihydroartemisinin, were investigated in patients with severe manifestations of falciparum malaria. METHODS: Six severe falciparum malariapatients with acute renal failure (ARF) and 11 without ARF were recruited into the study. They were treated with intramuscular artemether at a loading dose of 160 mg, followed by daily doses of 80 mg for another 6 days (total dose 640 mg). RESULTS:Patients with and without ARF showed a good initial response to treatment; the parasite and fever clearance times were 66(30-164) and 76(36-140) h [median(range)], respectively. None had reappearance of parasitaemia in their peripheral blood smear within 7 days of initiation of treatment. In comatosepatients, the time to recovery of consciousness was 51.6(22-144) h. Artemether was detected in plasma as early as 1 h after a 160 mg dose, and declined to undetectable levels within 24 h in most cases. Patients with ARF had significantly higher Cmax [2.38(1.89-3.95) vs 1.56(1.05-3.38) ng ml(-1) mg(-1) dose], AUC [35.4(22-52.9) vs 25.2(13.4-52.9) ng ml(-1) h mg(-1) dose], and lower Vz/F [5.45(3.2-6.9) vs 8.6(4.2-12.3) l kg(-1)] and CL/F [7.4(5.4-13.8) vs 19.1(8.5-25.1) ml min(-1) kg(-1)] when compared with those without ARF. In addition, t1/2,z was significantly longer in ARFpatients [7.0(5.5-10.0) vs 5.7(4.2-6.6) h]. The pharmacokinetics of dihydroartemisinin in the two groups of patients were comparable. CONCLUSIONS:ARF significantly modified the pharmacokinetics of intramuscular artemether. The changes could be attributed to either improved absorption/bioavailability, a reduction of systemic clearance, or a change in plasma protein binding of the drug.
Authors: J Karbwang; K Sukontason; W Rimchala; W Namsiripongpun; T Tin; P Auprayoon; S Tumsupapong; D Bunnag; T Harinasuta Journal: Southeast Asian J Trop Med Public Health Date: 1992-12 Impact factor: 0.267
Authors: J Karbwang; K Na-Bangchang; Y Wattanakoon; A Thanavibul; T Harinasuta Journal: Southeast Asian J Trop Med Public Health Date: 1994-12 Impact factor: 0.267
Authors: S Looareesuwan; B Oosterhuis; B M Schilizzi; F A E Sollie; P Wilairatana; S Krudsood; Ch B Lugt; P A M Peeters; J O Peggins Journal: Br J Clin Pharmacol Date: 2002-05 Impact factor: 4.335
Authors: T T Hien; T M E Davis; L V Chuong; K F Ilett; D X T Sinh; N H Phu; C Agus; G M Chiswell; N J White; J Farrar Journal: Antimicrob Agents Chemother Date: 2004-11 Impact factor: 5.191
Authors: K Na-Bangchang; J Karbwang; R Ubalee; A Thanavibul; S Saenglertsilapachai Journal: Eur J Drug Metab Pharmacokinet Date: 2000 Jul-Dec Impact factor: 2.441
Authors: Harin A Karunajeewa; John Reeder; Kerry Lorry; Elizah Dabod; Juliana Hamzah; Madhu Page-Sharp; Gregory M Chiswell; Kenneth F Ilett; Timothy M E Davis Journal: Antimicrob Agents Chemother Date: 2006-03 Impact factor: 5.191